A much-awaited treatment for postpartum depression, zuranolone, hit the market in December, promising an accessible and fast-acting medication for a debilitating illness. But most private health insurers have yet to publish criteria for when they will cover it, according to a new analysis of insurance policies. The lack of guidance could limit use of the drug, which is both novel — it targets hormone function to relieve symptoms instead of the brain’s serotonin system, as typical antidepressants do — and expensive, at $15,900 for the 14-day pill regimen. Lawyers, advocates, and regulators are watching closely to see how insurance companies will shape policies for zuranolone
Hence then, the article about a new 16 000 postpartum depression drug is here how will insurers handle it was published today ( ) and is available onKHN ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It? )